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Towards polymetallic lanthanide complexes as
dual contrast agents for magnetic resonance and
optical imaging
Elke Debroye and Tatjana N. Parac-Vogt*
Magnetic resonance imaging (MRI) is a popular imaging technique in medical diagnostics. With the
development of contrast agents, interest in its applications has grown tremendously. Significant effort has
been made in order to identify the most important parameters that enhance the relaxation efficiency of
MRI probes. Taking into account the requirements for an optimal magnetic performance, different contrast
agents have been synthesized and studied. Moreover, novel bimodal probes have been developed in order
to exploit the high sensitivity and resolution of optical microscopy with the ability of MRI to image opaque
samples. Employing this strategy enables the simultaneous visualization of the same biological structures at
different resolutions and depths. Throughout this review, different approaches used to improve relaxivity,
especially by increasing the molecular volume and hence the rotational tumbling time of the agent, are
highlighted. Several ways to obtain bimodal contrast agents are discussed in detail. Finally, lanthanide
complexes incorporating an aromatic unit permitting efficient sensitization of lanthanide luminescence in
combination with the relaxometric properties of gadolinium analogues are listed.
1 Introduction
Magnetic resonance imaging (MRI) has become an important
diagnostic technique in clinical medicine. It provides high quality
three-dimensional images of soft tissue with sub-millimeter
spatial resolution and no depth limit. Contrary to other diagnostic
techniques, like X-ray imaging or positron emission tomography
(PET), no harmful ionizing radiation is needed for MR imaging
since it is based on the principles of nuclear magnetic reso-
nance (NMR) spectroscopy. The obtained signal intensity in
MRI depends on the relaxation rate of protons of water
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molecules, which are on average 65% of a person’s weight. By
making use of three-dimensional magnetic field gradients,
anatomical information can be acquired from every selected
region in the human body. Differences among tissues can be
detected due to variations in water density, proton relaxation
times or water diffusion rates and the contrast can be improved
by the administration of a paramagnetic contrast agent (CA),
which enhances the rate of relaxation. In 1988, a first contrast
agent containing gadolinium(III) was approved for clinical
usage and nowadays, gadolinium-based complexes remain
the most commonly employed probes in MRI investigations,
comprising over 40% of all MRI scans in 2012.1 Gd(III) is a
paramagnetic metal ion with seven unpaired electrons resulting
in a high magnetic moment (7.94 mB) and its symmetric
8S7/2
ground state provides relatively long electron relaxation times.
These features make Gd(III) a very attractive component for
imaging applications. Since relatively high doses of gadolinium
of 0.1–0.3 mmol per kg body weight are needed2 and free
lanthanide(III) ions are known to be toxic (LD50 = 0.2 mmol kg
1
in mice), Gd(III) cannot be administered to a patient in
its aqueous form. For clinical examinations, the metal ion is
bound by a strongly coordinating ligand exhibiting high thermo-
dynamic stability and high kinetic resistance towards acid
catalyzed dissociation or transmetallation. The approved com-
mercial contrast agents contain acyclic or macrocyclic poly-
aminocarboxylates to which gadolinium is eight-coordinated by
nitrogen and oxygen donor atoms ensuring the stability. Across
the lanthanide series, the coordination number (CN) decreases
from nine for the light, to eight for the heavy trivalent metal
ions, with CN for Gd(III) = 9. As a consequence, one Gd(III)
coordination site remains available for the binding of a water
molecule, which is beneficial for the water proton relaxation
efficiency. The two most known complexes are the acyclic Gd(III)-
diethylene triamine pentaacetic acid (Gd-DTPA, Magnevists,
Bayer Schering Pharma AG) and the twelve-membered ring struc-
ture Gd(III)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(Gd-DOTA, Dotarems, Guerbet).
Important physicochemical factors influencing the proton
relaxivity of a gadolinium(III) complex will be discussed in the
first section. In order to improve the contrast of a MR image,
much effort has been made to increase the proton relaxation
rate of MRI contrast agents. In general, appropriate modulation
of the water exchange rate and the rotational correlation time
of the complex can significantly enhance the overall relaxivity.
A rigid macromolecule formed by covalent or non-covalent
interactions displaying an increased rotational correlation time
should be accompanied by a corresponding optimal water
residence time and within this search, no loss of the thermo-
dynamic stability or kinetic inertness of the complex may occur.
Despite the high spatial resolution and tissue penetration of
MRI, this technique suffers from a low sensitivity. Much effort
has been made to increase the sensitivity and to improve the
relaxivity, also at higher magnetic field strengths. However, in
certain cases it is necessary to validate imaging experiments by
more than one approach. As the optical imaging technique is
much more sensitive than MRI, the combination of these two
techniques may result in images which reveal more details
than when the two techniques are used separately. However,
simultaneous administration of two different kinds of contrast
agents needed for two imaging techniques may be problematic,
as they often may not exhibit the same pharmacokinetics.
Recently, the trend has shifted toward the development of
bimodal contrast agents in order to investigate samples in
exquisite detail.3 This review reports the most recent develop-
ments in the field of combinedMRI/optical probes and indicates
new areas that remain to be explored.
2 Design of efficient MRI contrast
agents
2.1 Physicochemical considerations
The efficacy of contrast agents with regard to their application
in MRI is defined by their relaxivity. This property describes the
ability of a 1 mM solution of CA to enhance the relaxation rate
of solvent nuclei in close vicinity of the paramagnetic entity,
which increases signal intensity in a magnetic resonance
image. Already in the period between 1948 and 1966, Solomon,
Bloembergen and Morgan among others explored in detail
the relaxation phenomena leading to the establishment of
the Solomon, Bloembergen and Morgan (SBM) theory.4–6 In the
presence of a paramagnetic compound, both the longitudinal 1/T1
and transverse relaxation rate 1/T2 of solvent (water) nuclei will
be increased. The observed solvent relaxation rate is defined by
eqn (1) consisting of a diamagnetic term (1/Ti,d) corresponding
to the relaxation rate in the absence of a contrast agent and a
paramagnetic term (1/Ti,p) representing the contribution of the
paramagnetic entity.
1
Ti;obs
¼ 1
Ti;d
þ 1
Ti;p
i ¼ 1; 2 (1)
The paramagnetic contribution is directly proportional to
the added gadolinium concentration:
1
Ti;obs
¼ 1
Ti;d
þ ri½Gd i ¼ 1; 2 (2)
where ri is the proton relaxivity expressed in units of mM
1 s1.
The paramagnetic relaxation of water protons is due to dipole–
dipole interactions between the proton nuclear spin and the
fluctuating local magnetic field generated by the unpaired
electron spins of the paramagnetic substance.7 This effect can
be separated into two components representing the inner and
outer sphere interactions:
1
Ti;p
¼ 1
Ti;p
 IS
þ 1
Ti;p
 OS
i ¼ 1; 2 (3)
In this equation, the superscript IS refers to the increased
relaxation rate of water molecules directly coordinated to Gd(III)
and OS stands for the paramagnetic influence on bulk water
molecules diffusing in the near environment of the complex. In
some cases, a second sphere contribution is taken into account
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arising from water molecules, which are hydrogen bonded to
the chelating unit, so eqn (3) can also be written as follows:
ri = r
IS
i + r
2nd
i + r
OS
i i = 1, 2 (4)
(in terms of relaxivities). The current design of new contrast
agents usually focuses mainly on modifying the parameters
responsible for the inner sphere longitudinal relaxivity r1,p
since these are thoroughly studied and can more easily be
evaluated compared to those governing the second and outer
sphere interactions.
The observable NMR signal reports on the proton longitudinal
relaxivity of bulk water protons which are in chemical exchange
with Gd(III)-bound water nuclei according to the following
equation:8
1
T1
 IS
¼ qPm
T1m þ tM (5)
Pm is the mole fraction of bound solvent nuclei, q is the
number of water molecules in the first coordination sphere of
the complex (also known as the hydration number), tM stands
for the residence time of the solvent nuclei in the inner sphere,
with kex = 1/tM, and T1m is the longitudinal relaxation rate of the
coordinated water protons. In the case of fast water exchange
(tM{ T1m), the relaxivity enhancement experienced by the bulk
nuclei is equal to that for the bound nuclei.
According to the Solomon–Bloembergen–Morgan equations,
the relaxation mechanism operating on the inner sphere water
protons can be subdivided into the dipole–dipole (DD) and
scalar or contact (SC) interactions.
1
Ti;m
¼ 1
TDDi
þ 1
TSCi
i ¼ 1; 2 (6)
The dipole–dipole mechanism (1/TDDi ) is governed by the
reorientation of the nuclear spin–electron spin vector, by
electron spin relaxation and by the water exchange rate, while
the scalar term (1/TSCi ) does not depend on the reorientation of
the molecule, but only on electron spin relaxation and water
exchange. The scalar contribution to the longitudinal relaxa-
tion rate is usually very small, since the bond formation in
Gd(III) complexes is ionic and the water proton is separated
from the metal ion by two bonds. Consequently, this term can
be neglected. On the other hand, the important dipole–dipole
interactions are influenced by a set of parameters, related to
each other as follows:
1
TDD1
¼ 2
15
gI
2g2mB
2SðS þ 1Þ
r6
3tc1
1þ oI2tc12ð Þ þ
7tc2
1þ oS2tc22ð Þ
 
(7)
where gI is the nuclear gyromagnetic ratio (42.57 MHz T
1 for
1H), g is the electron g factor, mB the Bohr magneton, S is the
spin quantum number (S = 7/2 for Gd3+), r is the electron spin –
proton distance and oI and oS are the proton and electron
Larmor precession frequencies respectively. The described
longitudinal relaxation mechanism is thus magnetic field
dependent via the Larmor frequencies: o = gB. The character-
istic correlation time tc relies on several molecular dynamic
processes such as the rotational correlation time (tR) or the
time needed for the reorientation of the metal – proton vector,
the water residence time in the first coordination sphere
(tM) and the longitudinal (T1e) and transverse (T2e) electronic
relaxation times for the metal ion, sometimes mentioned as
tS1 and tS2.
1
tci
¼ 1
tR
þ 1
tM
þ 1
Tie
i ¼ 1; 2 (8)
Referring to eqn (5), we can conclude that the longitudinal
relaxation rate (1/T1) will be enhanced if the overall correlation
time (tc) increases. If the water residence time is rather long
(T1m{ tM), then it will be the main factor limiting proton relaxivity.
In contrast, in the case of fast water exchange (tM{ T1m), the
relaxivity efficiency will depend on the relaxation rate of the
coordinated protons (T1m), which in turn is determined by tR,
tM and Tie. Maximum relaxivity is achieved when the inverse
correlation time 1/tci approaches the proton Larmor frequency
oI. The remaining challenge exists in the fact that tR, tM and
Tie have to be simultaneously optimized in order to obtain
highly efficient contrast agents. Fig. 1 illustrates the key factors
affecting proton relaxivity of a gadolinium(III) complex.
Thanks to extensive studies on a broad variety of gadolinium
complexes based on DTPA or DOTA scaffolds and their deriva-
tives, a relatively good insight into the essential requirements for
designing new contrast agents has been achieved. Numerous
papers and reviews have been published, describing not only the
determining factors for obtaining highly efficient contrast
agents, but also noting the difficulties that need to be taken
into account.1,9–15 In the next section, a short overview of the
most important tunable parameter and a discussion of corre-
sponding recent results are given.
2.2 Molecular tumbling
One of themost critical variables affecting relaxation at the currently
applied field strength (1.5 Tesla, 64 MHz) is the rotational
correlation time tR.
1 It was quickly found that the effective
correlation time tc (eqn (8)) was dominated by this parameter.
A higher tR value means slower molecular tumbling of the Gd(III)
chelate, which is favourable for the overall proton relaxivity.
Fig. 1 Physical parameters influencing the relaxation efficiency of MRI
contrast agents at the molecular level.
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A rough estimation of tR for spherical molecules can be obtained
from the Debye–Stokes equation:
tR ¼ 4pZa
3
3kBT
(9)
if the values of the molecular radius a and the viscosity Z
are known. However, this could lead to some problems since
the micro-viscosity may differ from the detected macroscopic
viscosity depending on the density of the molecules.
The rotational correlation time of small monomeric gado-
linium complexes used in clinical imaging is in the order of
0.1 ns, resulting in a rather inefficient relaxation of approxi-
mately 4–5 s1 mM1 at low magnetic fields and a significant
decrease in relaxivity at higher field strengths. However, the
trend in MR imaging is toward higher fields (7 T, 300 MHz)
since this results in a greater signal to noise ratio and increased
resolution. During the last couple of decades, different strategies
have been applied in order to slow down the molecular tumbling
of contrast agents achieving better magnetic properties, even at
increasing field strengths.14,17,18
The formation of supramolecular structures containing several
paramagnetic ions has been explored in our research group.
Copper[15]-metallacrown-5 gadolinium complexes derived
from alpha-aminohydroxamic acids have been studied, for
which a linear relationship between the relaxivity and the
molecular mass of the metallacrown complex was found.19 A
different strategy comprises the formation of a high-molecular
weight tetra-metallic complex upon self-assembly of three
phenantroline-substituted DTPA units around one iron(II) ion
improving relaxivity to 9.5 s1 mM1 at 20 MHz. In vivo
evaluation indicated potent contrast enhancement in organs
including the liver.20
Monomeric Gd(III) chelates have been conjugated to macro-
molecular carriers, such as polymers leading to a notable increase
of tR. It has been found that the rotational dynamic rate in
hyperbranched polymers lies in between the values obtained
for linear (fast rotation) and star polymers (slow rotation).
However, the hyperbranched structures possess the shortest
tM value since these are not too densely packed, resulting
in better relaxivity r1.
21 Numerous variations of dendrimer-
based contrast agents for site-specific MR imaging have been
synthesized.16,22 The hydrophobic structures display a prefer-
ence for accumulation in liver and kidney, while functionalisa-
tion with polyethylene glycol allows imaging of the lymphatic
system (Fig. 2).
Likewise, conjugates of Gd(III)-based paramagnetic centres
attached to monosaccharide sugars23 achieving a molecular
weight of 3500 g mol1 or of polysaccharide inulin24 of which
each monosaccharide unit was attached to one Gd(III) chelate,
have been studied. The average molecular weight of the latter
conjugate equalled 23 110 g mol1 and the average number of
Gd(III) ions per molecule was 24. For both systems, strong
enhancements of the relaxation rates, up to 23 s1 mM1 at
20 MHz, were obtained.
The incorporation of amphiphilic Gd(III) complexes into
slowly tumbling micelles or liposomes also led to higher proton
relaxivities.12,25 The aggregates are formed by hydrophobic
interactions between the lipid tails while the hydrophilic moi-
eties of the molecules face water. The formation of a micellar
monolayer structure or a liposomal bilayer encapsulating an
aqueous core depends on the nature and the relative sizes of
the hydrophobic and hydrophilic parts. Very often, cholesterol
or phospholipids are added in order to acquire more stable and
monodisperse aggregates. During the last decade, many para-
magnetic micelles of about 20–30 nm have been synthesized,
achieving relaxivities of 18–25 s1 mM1 at 20 MHz and
37 1C.27–30 The liposomal vesicles as shown in Fig. 3 benefit
from high observed relaxation rates from 10–15 s1 mM1 up to
30 s1 mM1, under the same conditions induced by the Gd(III)
complexes entrapped in the inner aqueous cavity, in addition to
the chelates at the external periphery.26,31–33
A relatively accessible approach to restrict rotational motion
involves non-covalent binding of the chelating ligand to proteins,
such as human serum albumin (HSA) – the most abundant
protein in blood. The reported albumin-targeted angiography
agents generally display improved relaxivity (8–1534,35 to even
4036 s1 mM1 at 37 1C and 20 MHz) in the presence of 4% HSA.
However, after elucidating the molecular mechanism, it was
found that the protein itself can diminish hydration of the metal
complex and/or the rate of water exchange due to limited access
to the water binding site.10,37
Very high relaxivity values were obtained by inserting Gd(III)
ions into nano-sized particles due to the fixation of numerous
paramagnetic centres in a compact volume.2 The surface of gold
nanocrystals has been coated with thiol derivatives of DTPA38,39
or DTTA40 leading to 2–3 nm particles with approximately 150
chelating units able to bind a gadolinium ion (Fig. 4). The overall
Fig. 2 Examples of a hydrophobic G3-24Gd-DTPA (left) and hydrophilic
G3-12Gd-DTPA-12mPEG (centre) dendrimer conjugated with Gd(III)-
DTPA chelates.16
Fig. 3 Illustration of a paramagnetic liposome loaded with amphiphilic
Gd(III) complexes.26
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relaxation enhancement per mM nanoparticle was calculated to
be 600 and 3000 s1 respectively. Immobilizing Gd(III) ions
inside GdNaY-zeolite cavities showed increased proton relaxivity,
but the efficiency was limited to 33 s1 mM1 by slow diffusion
of water molecules from the interior of the silica-based particle
(60–100 nm) to the bulk water.41 This limitation could be over-
come by increasing the volume of the inner cages, improving
the paramagnetic relaxation enhancement to 45 s1 mM1.42
Another family of silica nanoparticles consists of nanocontainers43
and mesoporous nanoparticles.44 The cylindrically shaped systems
expose about 370 Gd(III)-DOTA units per zeolite crystal exhibiting
an overall relaxation rate of 11 000 s1 per mM nanoparticle.
One more example comprises ultrasmall (5–10 nm) Gd2O3 nano-
crystals capped with diethylene glycol chains.45,46 The relaxation
enhancement per particle reaches 39800 s1 mM1.
Despite the significant efforts in order to increase the molecular
tumbling time of the MRI contrast agent, the theoretical maximum
relaxation enhancement per Gd(III) ion (B100 mM1 s1) has
not yet been reached.1 Unfortunately, the rigidity of the formed
macromolecular compound is very often accompanied by local
motion of the gadolinium complex. Careful attention should be
given to the flexibility of the linker group during the design of
new high-molecular weight contrast agents. The total rotational
dynamics can be moderated by considering the construction of
polymer conjugates or via multilocus binding of the complex
resulting in better fixation at the target micelles, liposomes33
or proteins.47
3 Design of MRI/optical contrast
agents
Optical imaging is characterized by a low detection limit in the
sub-micromolar scale versus millimolar for commercial T1
contrast agents. Optical imaging offers good resolution as well,
but it is limited by a low tissue penetration. Light situated in
the visible region (400–700 nm) cannot propagate more than
5 mm in tissue whereas light of higher wavelengths is less
absorbed by physiological chromophores such as hemoglobin
and melanin.48 Numerous reports affirm that NIR light of 700–
900 nm can cross a few centimetres of tissue by multiple
scattering, enabling in vivo fluorescence imaging.49,50 Luminescent/
MRI bimodal agents have been developed exploiting the
emissive properties of organic dyes, transition metal complexes
or lanthanide ions.3,51–53 By this approach, the high resolution of
magnetic resonance imaging and the high sensitivity of optical
imaging are combined in one single probe displaying the same
biodistribution for each diagnostic technique.
3.1 Attachment of a MRI contrast agent to an organic dye
Conjugate peptides containing a Cy5.5-like dye and a Gd-DTPA
chelate54 or fluorescein and Gd-DOTA (Fig. 5)55 have been
reported. Good in vivo fluorescence properties and an average
four-fold increase of the longitudinal relaxation rate compared
to the parent gadolinium chelates were obtained. Another approach
consists of the synthesis of Gd(III) hydroxycarbonate nanoparticles
coated with a silica shell embedded with rhodamine B (RhB).56
These particles behave as moderate T1 or T2 relaxing contrast
agents. They are clearly visible via the characteristic red emis-
sion of RhB with a low degree of photobleaching due to their
incorporation inside the silica matrix. Furthermore, BODIPY-
DOTA derivatives have been designed57 and can also be employed
as a dual MR/optical imaging reporter characterized by con-
siderably high quantum yields (20–50% in water). Intracellular
delivered star polymers containing a blue fluorescent fluorene
core were modified in order to chelate gadolinium(III) or
europium(III). Rapid water exchange in the highly hydrated star
polymer provided large ionic relaxivities up to 84 s1 mM1 at
20 MHz and 310 K.58
3.2 Heteropolymetallic complexes
The synthesis of a ditopic ligand containing a gadolinium
coordinating unit and a moiety with affinity for luminescent
transition metals allows the formation of a self-assembling
bimodal heterometallic complex. In 2008, Faulkner et al. linked
Gd(III)-DOTA to a rhenium(I) complex exhibiting red lumines-
cence59 (Fig. 6a). A relatively long emissive lifetime (tLMCT) of
0.24 ms is observed for Gd3Re(Bpy)(CO)3, since there is no
competitive quenching pathway through the lanthanide ion.
The high relaxivity (8.6 s1 mM1 at 500 MHz) in aqueous solution
is in line with the existence of a diaqua complex which tumbles
slowly in solution. Later, six Gd(III)-DTTA complexes have been
assembled around ruthenium(II) via three bipyridine coordinating
units (Fig. 6b). The NMRD profile of Ru(Gd2bpy-DTTA2)3
Fig. 4 Covalent binding of Gd(III)-DTTA to a gold nanoparticle.2,40 Fig. 5 A cell penetrating peptide, functionalized with a galactose moiety
to report on the b-galactosidase enzyme, that incorporates two imaging
moieties Gd-DOTA and fluorescein.55
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showed a relaxivity hump between 10 and 100 MHz character-
istic of slowly rotating molecules. The quantum yield of
Ru(bpy)3 compounds in aqueous solutions is modest, lies in
the range 0.001–0.1%, depending on pH and temperature, and can
be accompanied by formation of singlet oxygen.60 Our group has
designed novel metallostar complexes in which the longitudinal
relaxivity of Gd(III)-DTPA was combined with a green-emissive
titanium(IV) catecholate61 or aluminum(III) 8-hydroxyquinoline62
core (Fig. 6c and d). The complex (Gd4)3Ti(H2O)3 exhibited green
broad-band emission with a maximum of 490 nm but with a
relatively low absolute quantum yield of 0.054%. The decreased
tumbling rate of the supramolecular complex led to an
enhanced r1 relaxivity up to 12.3 s
1 mM1 per Gd(III) ion at
20 MHz and 310 K that corresponds to 36.9 s1 mM1 per
metallostar molecule. Formation of the metallostar compound
(Gd5)3Al(H2O)3 resulted in a r1-value of 10.9 s
1 mM1 per
Gd(III) ion, corresponding to 32.7 s1 mM1 per heteropoly-
metallic complex. In addition to the high relaxivity values,
(Gd5)3Al(H2O)3 exhibited green broad-band emission lumines-
cence upon excitation at 367 nm. Heteropolymetallic complexes
based on a ruthenium(II) 1,10-phenantroline centre were also
synthesized and are depicted in Fig. 6e and f.63,64 The r1
relaxivities of [Ru(bpy)2]2GdDTPA(ph-phen)2 and (Gd-DTPA-
ph-phen)3Ru per Gd(III) ion at 20 MHz and 310 K were equal
to 7.0 and 12.0 s1 mM1, respectively. Both compounds exhibited
bright-red luminescence centred at 610–620 nm and the quantum
yields were found to be 4.7% and 4.8%. The luminescence lifetime
of [Ru(bpy)2]2GdDTPA(ph-phen)2 equals 0.54 ms which is long
enough to permit reasonable gating of any fluorescent background
(for which lifetimes ofo10 ns are typical) in applications such
as time resolved microscopy. Unfortunately, in general, the
broad emission bands and relatively short luminescence life-
times (o1 ms) of transition metal chelates are less favourable
for in vivo measurements since the observed emission can be
hardly differentiated from background autofluorescence. Relaxa-
tion values and photophysical details of the discussed f–d hetero-
polymetallic complexes are summarized in Table 1.
3.3 Bimodal lipophilic aggregates
The two diagnostic features were also combined into supra-
molecular aggregates such as micelles or liposomes. The surface
of liposomes encapsulating several magnetite cores has been
covered with Gd(III) complexes resulting in a very high r2/r1
ratio. The high flexibility of the lipid bilayer and the ease of
preparation enable the composition to be fine-tuned and permit
fluorescent moieties to be incorporated in the conjugates.65
Likewise, iron oxide nanoparticles and hydrophobic luminescent
polymers were encapsulated in micelles. They emit across the
visible spectrum with a relatively low quantum yield of 1.2%,
which is typically a problem with fluorescent-magnetic nano-
composites. InMRI studies, they exhibited a shortening effect on
the T2 relaxation time.
66 Liposomes containing Gd-DTPA directly
attached to bis(stearyl) and fluorescent lipids could be detected
via in vitro and in vivo optical imaging and were also tested
for MRI. The relaxivity per millimolar nanoparticle has been
Fig. 6 Chemical structures of lanthanide-transition metal heteropoly-
metallic complexes for potential bimodal MR/optical imaging.59–64
Table 1 Relaxometric and photophysical key data of f–d heteropolymetallic complexes depicted in Fig. 6
Relaxometric Ln(III) Luminescent metal ion r1
a (s1 mM1) lexc (nm) Quantum yield F
b (%)
Gd3Re(Bpy)(CO)3
59 GdIII ReI 8.6 (500 MHz) 337 —
Ru(Gd2bpy-DTTA2)3
60 GdIII RuII 23.0 293 0.1
(Gd4)3Ti(H2O)3
61 GdIII TiIV 12.3 380 0.05
(Gd5)3Al(H2O)3
62 GdIII AlIII 10.9 367 0.52
[Ru(bpy)2]2GdDTPA(ph-phen)2
63 GdIII RuII 7.0 440 4.7
(Gd-DTPA-ph-phen)3Ru
64 GdIII RuII 12.0 450 4.8
a Relaxivity r1 per millimolar Gd(III) at 20 MHz and 310 K unless stated otherwise.
b Quantum yield relative to a standard solution.
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estimated to be 2000 s1 mM1.67 In order to avoid the use
of two separate signaling compounds, more robust bimodal
PEGylated liposomes were made out of a lipid molecule
covalently bound via a Gly–Lys linker to Gd-DOTA and rhod-
amine. In vitro labeling of cells could be monitored by fluores-
cence microscopy and resulted in an over six-fold tumour to
muscle signal enhancement.68 A key concern is to ensure that
the Gd-based probes remain in the aqueous compartment in
order to have access to water, while it has to be taken into
account that the environment can suppress the emission
intensity of the fluorophores.
3.4 Nanoparticles
Nanoparticles for dual imaging are typically formed starting
from existing particles that already possess one imaging func-
tionality. An extra modality is then introduced in a spherical
way around the core material. Numerous bimodal systems
based on core–shell quantum dots or iron oxides have been
comprehensively described in several reviews.3,51,69 Quantum
dots expose a large amount of free amines over the entire surface,
so that gadolinium chelates can easily be attached. Hydrophobic
QDs coated with the tripeptide glutathione (Fig. 7)70 or with
a PEGylated silica shell71 were labeled with Gd-DOTA. The
Gd-ion relaxivities r1 and r2 at 60 MHz are up to 23 s
1 mM1
and 54 s1 mM1 respectively, while NIR efficiency of 8.4% resulting
from the synthesized nanomaterial was obtained. Besides the
coupling of an iron oxide to organic fluorophores such as
rhodamine,72 AlexaFluor,73 oligothiophene74 or Cy5.5,75 the
T2 superparamagnetic particles can also be encapsulated in a
shell, including the most popular silica shell. Porous silica
layers enable good photon-transparency, water solubility and a
large load of a variety of molecules like the organic dyes,
fluorescein isothiocyanate76 and rhodamine77 or inorganic
fluorophores such as terbium complexes.78 Alternatively, it is
possible to have both imaging probes in the same matrix
material by inserting the desired components into a nanocrystal.
An anti-Stokes type emission has been observed with (Gd,Yb,Tb)PO4
nanocrystals, which have been synthesized via a hydrothermal
method. Relaxometric measurements reveal that they are efficient
T2-weighted contrast agents while strong green luminescence
of terbium(III) is generated by two-photon infra-red excitation.79
Another approach involves hybrid silica nanospheres containing
a luminescent ruthenium-bipyridine core and a paramagnetic
coating of silylated gadolinium complexes. At 60 MHz, they
exhibit a longitudinal relaxivity of 19.7 s1 and a transverse
relaxivity of 60.0 s1 per millimolar Gd(III).80 Because of the high
payload of Gd-DTTA chelates, the nanoparticles display r1 and
r2 values of 2.0  105 and 6.1  105 s1, respectively, on a per
millimolar particle basis.
4 Lanthanide-based bimodal systems
Although significant improvements concerning the utility of
dual imaging reporters have been achieved, practical applica-
tions of the aforementioned conjugates are limited due to short
luminescence lifetimes (100–300 ns), a small Stokes shift and
poor resistance to photobleaching. During the last decade,
lanthanide-based systems combining magnetic and optical
properties have been attracting increasing attention.88 Besides
the excited state lifetimes in the range of milliseconds (allowing
filtering from short lifetime autofluorescence), lanthanides
display a sharply spiked emission spectrum and a large energy
difference between their emission bands and the absorption bands
of the coordinated ligands, resulting in an exquisite luminescence.
One must take into account that the f–f transitions of Ln(III) ions
are characterized by low molar absorption coefficients since they
are Laporte forbidden. For this reason, it is necessary to integrate
an appropriate chromophore (aromatic unit) into the chelating
ligand to trigger a process called ‘sensitization’. Upon absorption
of light of a certain wavelength, the ligand is excited to the
singlet excited state. The captured energy can be transferred to
the lanthanide ion (singlet energy transfer), to the triplet state
(intersystem crossing), or can be seen as fluorescence through an
immediate decay to the ground state. The triplet state can
subsequently pass the energy to the lanthanide ion or decays
to its ground state by phosphorescence. Generally, although
there are some exceptions, energy is transferred via the triplet
state because the intersystem crossing is forced by the neigh-
bouring paramagnetic lanthanide ion. In addition, energy trans-
fer via the singlet state is not as fast as fluorescence or
intersystem crossing. The emission intensity of lanthanide
luminescence can significantly be reduced by a non-radiative
energy dissipation via the vibronic modes of solvent molecules.
Typically, this occurs by harmonic oscillators in the inner
coordination sphere or in the near vicinity of the metal complex.
The most common and efficient quencher is the O–H oscillator. In
order to minimize this non-radiative decay effect, the lanthanide
ion should be effectively shielded from the solvent by using
chelating ligands that firmly bind and encapsulate the metal ion.
It is not surprising that, apart from the well-known gadolinium-
basedMRI contrast agents, a selection of lanthanide compounds
is used as luminescent probes in the visible and near infrared
region for bioassay and live-cell microscopy.89,90
Fig. 7 Gd(III)-DOTA functionalized cadmium-based quantum dots with a
glutathione coating.70
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4.1 Mixed lanthanide systems
Mixtures of complexes in which the ligand is coordinated to
paramagnetic gadolinium(III) or to lanthanide(III) ions emitting
in the visible or NIR region have been intensively studied for
their magnetic resonance and optical abilities.
A pyridine-based DTPA substrate (Fig. 8a) allowing heptadentate
coordination to lanthanide ions and bishydration of the complex
has been synthesized. Improved MRI properties were obtained
for the corresponding Gd(III) complexes (6.21 s1 mM1) and
also NIR luminescence could be observed after complexation
with neodymium(III). A luminescence quantum yield of 0.01%
indicated that the presence of two water molecules bound to the
Ln(III), beneficial for MRI applications, is not an absolute limita-
tion for the development of NIR luminescent probes.81 The same
ligand was attached to the surface of silica nanoparticles which
was subsequently loaded with Gd(III) as well as Eu(III)/Tb(III)
for relaxometry and visible luminescence, respectively.82 The
aromatic backbone onto the silica surface enhanced the emis-
sion quantum yield of the Eu(III)-containing nanoparticles
fivefold (0.05%) compared to similar systems without aromatic
antennae. The Gd(III) paramagnetic relaxation at 20 MHz and
310 K equaled 7.95 s1 mM1. Derivatives of the pyridine-based
DTPA ligand with an extra methoxy or triazole ring system
(Fig. 8b–d) led to similar quantum yields of 0.01–0.02% for the
NIR-emitting Nd(III) and Yb(III) complexes. Especially the syn-
thon with a conjugation-expanding phenyl group displayed a
somewhat increased sensitivity due to the higher extinction
coefficient. Furthermore, the shift of the excitation wavelengths
to higher values was beneficial for biological applications.83
In vivo toxicity studies revealed that the bis-hydrated complexes
were non-toxic and that they could be safely used for both
magnetic resonance (MR) and optical imaging applications.
The luminescent properties were further optimized by the
substitution of the pyridine core by isoquinoline (Fig. 8e and f).
The excitation wavelength shifted over 100 nm toward lower
energy in comparison to the pyridine-based analogue providing
more adapted NIR emitting complexes for biological studies.
The luminescence quantum yields of the Nd(III) (0.013–0.016%)
and Yb(III) chelates (0.028–0.040%) are in the range of non-
hydrated complexes, despite the presence of two inner-sphere
water molecules. Nevertheless, good stability was obtained and
promising r1 values of 8.5 s
1 mM1 for the corresponding
gadolinium(III) compounds were acquired.84
Despite the coordination of two water molecules, NIR emis-
sion could also be observed after complexation of the tripodal
hydroxyquinolinate ligand, depicted in Fig. 8g, to Nd(III) or Yb(III).
Fig. 8 Chemical structures of chelating ligands for dual imaging applications.81–87
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Unfortunately, a slow water exchange limited the expected high
relaxivity for this bishydrate complex. On the other hand, the
octadentate ligand based on triazacyclononane and 8-hydroxy-
quinolinate/phenolate binding units (Fig. 8h) was found to lead
to gadolinium complexes with a relaxivity of 9.1 s1 mM1 at
20 MHz as a result of a long rotational correlation time, fast
water exchange and slow electronic relaxation. The ligand was
also a good sensitizer for near-IR emission of neodymium and
ytterbium ions, displaying luminescence quantum yields up to
0.02%.85 Ln(III) complexes (Ln = Gd, Eu, Tb) of the ligands
DTPA-bis-p-toluidine-amide, DTPA-bis-6-coumarin-amide, DTPA-
bis-1-naphthylmethyl-amide and DTPA-bis-4-ethynylphenyl-amide
(Fig. 8i–l) were prepared and studied for their bimodal MRI/
optical properties.86 Eu(III) and Tb(III) derivatives in aqueous
solutions exhibit characteristic red and green emission, respec-
tively, with quantum yields of 0.73% for Eu(III)–DTPA-BNaphA
and 2.5% for Tb(III)–DTPA-BEthA. The relaxivity of the Gd(III)
complexes was improved compared to Gd-DTPA (5.5 s1 mM1
versus 3.8 s1 mM1 at 20 MHz and 310 K) due to a general
increase of the rotational tumbling time, tR. Moreover, inter-
action studies in 4% HSA solutions revealed a further increase of
relaxivity to values of 19 s1 mM1 caused by a further decrease
of molecular motions. Gd(III) and Eu(III) complexes of two DTPA
bisamide derivatives functionalized with p-dodecylaniline and
p-tetradecylaniline (Fig. 8m and n) have been assembled with
phospholipid DPPC and surfactant Tween 80s forming mixed
micelles. Taking into account the sensitivity difference between
magnetic resonance and optical imaging techniques, several
ratios of Gd and Eu complexes were combined in one single
micelle and their optical and relaxometric properties have been
characterized in detail. The Eu(III) micelles exhibited quantum
yields in the range of 1.0% and the relaxivity per Gd(III) ion reaches
a maximum value of 16.0 s1 mM1 for the Gd-DTPA-BC14PheA
assemblies, due to large tR values of 6.6 ns. The concentration
ratio of 20 : 1 Gd/Eu compounds in the micelles provided the
optimal required bimodal performance which can be useful
in the search for other potential bimodal assemblies.87 The
most relevant data regarding relaxometric and photophysical
features of the aforementioned lanthanide complexes are listed
in Table 2.
Gd(III), Eu(III) and Tb(III) tris(amide) derivatives of DOTA in
which one of the macrocyclic backbone nitrogen atoms has been
replaced by a pyridine nitrogen (Fig. 9a), have been examined as
potential contrast agents for imaging applications. The gadolinium
chelates displayed high proton relaxivities of 7.9 s1 mM1 at
20 MHz and 310 K due to rapid water exchange and a large
outer-sphere contribution, while the europium and terbium
complexes revealed clearly visible luminescence for the q = 2
species.91 An aryl-phosphonate moiety was attached to DOTA
since it can directly coordinate to the lanthanide ion maintain-
ing a low hydration number and it acts as an effective antenna
sensitizing green Tb(III) luminescence, obtaining quantum
yields of 0.2–0.3% (Fig. 9b). Despite the eight-fold coordination
to Gd(III), moderate relaxation properties around 5.0 s1 mM1
including second sphere contributions were obtained. Struc-
tural variations of the ligand, such as the alkyl chain length or
the nature of the phenolic para substituent, enable further fine
tuning possibilities.92 A somewhat different approach starts from
dinuclear Gd(III), Eu(III) or Tb(III) complexes comprising DO3A
units linked by a 4,40-dimethyl-2,20-bipyridine or a 2,6-bis(1H-
pyrazol-1-yl)pyridine spacer (Fig. 9c and d). NMRD profiles char-
acteristic of slowly tumbling compounds with high relaxivities
between 10 and 60 MHz were observed due to the formation
of nanosized aggregates. The relaxivity recorded at 20 MHz
and 298 K equaled 13.7 s1 mM1 per molecule with two
coordinated Gd(III) ions. The overall luminescence quantum
Table 2 Relaxometric and photophysical key data for complexes based on ligands depicted in Fig. 8
Ligand Relaxometric Ln(III) Luminescent Ln(III)
r1
a (s1 mM1)
at 20 MHz
r2
b (s1 mM1)
at 500 MHz lexc (nm) Quantum yield F
c (%)
Py81 GdIII NdIII/YbIII 6.2 — 267 0.01/0.02
SiO2@APS/PMN
82 GdIII EuIII, TbIII 7.9 56.4 270 0.05
MeOPy83 GdIII NdIII/YbIII — — 250 0.01/0.02
C5TPy83 GdIII NdIII/YbIII — — 290 0.01/0.02
PheTPy83 GdIII NdIII, YbIII — — 320 0.01
Isoquin84 GdIII NdIII/YbIII 8.5 — 320 0.02/0.04
diMeO-isoquin84 GdIII NdIII/YbIII — — 360 0.02/0.04
thqN-SO3
85 GdIII NdIII, YbIII 5.7 — 375 0.01
dhqtcn-SO3
85 GdIII NdIII, YbIII 9.1 — 375 0.02
BTolA86 GdIII EuIII/TbIII 4.1 — 280 0.3/0.6
BCoumA86 GdIII EuIII/TbIII 5.1 — 330 0.6/1.2
BNaphA86 GdIII EuIII/TbIII 6.4 — 292 0.7/1.0
BEthA86 GdIII EuIII/TbIII 5.7 — 290 0.6/2.5
BC12PheA Mic
87 GdIII EuIII 14.2 — 290 1.0
BC14PheA Mic
87 GdIII EuIII 16.0 — 290 1.1
BTolA86 DyIII DyIII 0.2 19.0 280 0.3
BCoumA86 DyIII DyIII 0.1 19.5 330 0.4
BNaphA86 DyIII DyIII 0.1 13.2 292 0.3
BEthA86 DyIII DyIII 0.1 27.4 290 0.5
BC12PheA Mic
87 DyIII DyIII 0.2 36.0 290 1.0
BC14PheA Mic
87 DyIII DyIII 0.2 33.4 290 1.0
a Relaxivity r1 per millimolar Gd(III).
b Relaxivity r2 per millimolar of Ln(III) ion.
c Quantum yield relative to a standard solution.
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yields were determined to be up to 0.08% for Eu(III) and
0.50% for Tb(III), pointing to an effective sensitization of the
metal ion, especially for the compounds exhibiting terbium-
centred emission.93 Relaxivity values and luminescence details
of the DOTA derivatives are collected in Table 3.
NIR and magnetic resonance studies have been performed
exploiting the properties of the dysprosium(III) and ytterbium(III)
ions. These lanthanides were chelated with a hexadentate ligand
and subsequently conjugated to an esteramide dendrimer in
order to improve bioavailability and solubility. At 60 MHz and
310 K, the Dy-containing macromolecules had the largest r1
relaxivity, 7.60 s1 mM1, while the Yb-analogues apparently
displayed the largest r2 relaxivity, 23.0 s
1 mM1. Furthermore,
a Yb(III) NIR quantum yield of 0.2% was measured, thereby
establishing an ytterbium-based bimodal NIR/T2 contrast
agent.94 The six DTPA bisamide derivatives (Fig. 8i–n) have also
been coordinated to dysprosium(III) and the magnetic and optical
properties of the corresponding complexes and micelles were
examined in detail.95 The complexes displayed characteristic
Dy(III) emission with quantum yields of 0.3–0.5% and quantum
yields up to 1% were obtained for the micelles. The transverse
relaxivity r2 per Dy(III) ion at 500 MHz and 310 K reaches a
maximum value of 27.4 s1 mM1 for Dy-DTPA-BEthA and
36.0 s1 mM1 for the Dy-DTPA-BC12PheA assemblies which is
about 40-fold higher compared with a value of 0.8 s1 mM1 for
Dy-DTPA. The efficient T2 relaxation is sustained by the high
magnetic moment of the dysprosium ion, the coordination of
water molecules with slow water exchange kinetics and long
rotational correlation times. These findings open the way to the
further development of bimodal optical and magnetic resonance
imaging probes starting from single lanthanide compounds.
4.2 Heterometallic lanthanide complexes
The controlled site-selective synthesis of heterometallic lanthanide
complexes remains a challenge due to the very similar coordination
behaviour across the lanthanide series. For this reason it is
important to highlight a few known approaches to successful
preparation of this type of compounds. In a first example, two
Tb(III)-DOTA chelates bearing a benzyl function have been linked
by a DTPA binding site. Subsequently, Yb(III) was incorporated
into the DTPA unit, yielding a trinuclear complex containing two
different luminescent ions. After direct excitation of terbium
at 488 nm, near-IR sensitized emission of ytterbium at 980 nm
could be observed, inferring energy transfer between the two
lanthanide metals due to their close proximity96 (Fig. 10a).
On the other hand, europium(III) and terbium(III) have been
consecutively integrated into a branched tetrapeptide-based
DOTA/DTPA bis-chelate. The luminescence properties were com-
pared in a series of alcohol solvents, and the Eu(III) emission
band increased at the expense of Tb(III) emission with decreasing
solvent polarity, offering potential applications in time-resolved
solvent polarity sensing97 (Fig. 10b). Orthogonal protection of
equivalent binding sites in a given ligand has been reported to
allow selective lanthanide coordination. Fig. 10c depicts the
discretely synthesized Tb(III)–Yb(III) bismetallic complex with a
4-aminoaniline bridge between two DOTA sites. The compound
displayed sensitized luminescence in the visible and near IR
region from both the Tb(III) and Yb(III) centres, respectively.98
Another strategy concerns the linkage of related bismetallic
complexes containing Yb(III) or Nd(III) using diazotation reactions.
Upon formation of the tetrametallic compound, an azo-dye is
simultaneously generated which ensures efficient lanthanide
sensitization leading to emission in the near IR region of
the spectrum99 (Fig. 10d). Binuclear lanthanide complexes as
presented in Fig. 10e have been obtained through ‘‘click’’-
chemistry.100 Copper catalyzed cycloaddition reactions with
alkyne-functionalized Ln(III)-DO3A and benzyl azides lead to
Fig. 9 DOTA-based scaffolds allowing bimodal MR/optical imaging.91–93
Table 3 Relaxometric and photophysical key data of complexes based on DOTA compounds shown in Fig. 9
Ligand
Relaxometric
Ln(III)
Luminescent
Ln(III)
r1
a (s1 mM1)
at 20 MHz lexc (nm)
Quantum
yield Fb (%)
PCTA-(gly)3
91 GdIII EuIII, TbIII 9.9 284 0.05
PhePO3
92 GdIII TbIII 5.0 300 0.2–0.3
BiPy93 GdIII EuIII/TbIII 5.1 287 0.08/0.25
BPyrazolPy93 GdIII EuIII/TbIII 6.9 287 0.01/0.50
a Relaxivity r1 per millimolar Gd(III).
b Quantum yield relative to a standard solution.
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the formation of linked lanthanide complexes incorporating
triazole units. It has been found that coordination of one of the
triazole nitrogen atoms to the metal centre is able to switch on
the luminescence or to change the spectroscopic properties by a
change in the coordination environment. As an alternative, the
Ugi four-component reaction has been applied to synthesize
ditopic chelators by reacting different aldehydes, isocyanides
and DOTAmonoamides as amino and acid components (Fig. 10f).
Relaxivity studies on the Gd2-complexes with R = octadecyl
revealed enhanced T1 relaxation values of 20.0 s
1 mM1 at
20 MHz and 310 K due to aggregation of the lipophilic structures
forming micelles or even 38.1 s1 mM1 via non-covalent inter-
actions in the presence of HSA.101 The introduced ‘‘click’’- and
Ugi-reactions have been combined in a novel strategy creating
tetranuclear lanthanide complexes containing two dysprosium
ions, a terbium and a europium ion102 (Fig. 10g). The emission
spectrum of the Dy2TbEu compound exhibits the luminescence
transitions from the three different lanthanide ions. In such
systems, the overall emission spectrum can be tuned by varying
the building blocks and their relative distances.
Several routes towards dual MR/optical imaging lanthanide-
based systems have been explored. An aryl-group, functioning
as the antenna, has been directly integrated into an acyclic
polyaminocarboxylate chelator which was attached to a DOTA
ring structure (Fig. 11a). The longitudinal relaxivity of the
compound incorporating Gd(III) in the DOTA unit was calcu-
lated to be 5.48 s1 mM1. The antenna was able to sensitize
both Eu(III) as well as Tb(III) when coordinated to the ligand.
Compared to DOTA, the acyclic moiety is less kinetically and
thermodynamically stable, however, the required emission and
relaxometric characteristics have been demonstrated.103 As an
alternative, two DOTA units bearing Gd(III) and Nd(III), Er(III) or
Yb(III) were linked together by a diaminoanthraquinone (AQ)
chromophore (Fig. 11b). The 1,4-diamino-substituted AQ has
been compared with the 1,5-substitution pattern concerning
relaxometric and optical properties.104 DNA intercalation studies
Fig. 10 Sequentially metallated heteronuclear lanthanide complexes.96–102
The coordination bonds have been omitted for clarity.
Fig. 11 Chemical structures of selectively coordinated lanthanide-based
bimodal systems.103–106 The metal coordination and Ln–water bonds have
been omitted for clarity.
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showed that stronger binding interactions were obtained
with 1,4-diamino-substituted AQ, promoting a relaxivity of
5.8 s1 per mM Gd(III) at 20 MHz and 310 K when bound to
the macromolecular DNA duplex due to slower rotational rates
and the immobilization of the Gd(III) unit. Characteristic
lanthanide-based emission in the near IR region could be
observed for both chromophores, however, the 1,4-substituted
AQ species possessed longer wavelength visible absorption. In
2011, Lewis et al.105 demonstrated the importance of the
proximity of the lanthanide centres during the design of multi-
modal probes. In their work, two DTPA-bis-p-thiophenol amide
derivatives were assembled via two disulphide bonds (Fig. 11c).
The macrocyclic compound in which Gd(III) and Eu(III) were
integrated displayed a 15% reduction in europium emission
intensity compared to the non-macrocyclic Eu(III) and Gd(III)
complexes. This observation has been ascribed to the increased
rate of non-radiative emission pathways induced by the presence
of internal gadolinium. Nevertheless, regarding the imaging
sensitivities, the proposed structures provide interesting scaf-
folds for bimodal MR/optical applications. A novel synthetic
strategy towards a heteropolymetallic lanthanide complex
with selectively incorporated gadolinium and europium ions
has been reported. For this purpose, a ditopic ligand able
to coordinate with two different lanthanide ions was used.106
A DTPA-based moiety taking care of gadolinium(III) chelation
is linked via an amide bond to a pyridine-2,6-dicarboxylate
derivative ensuring self-assembly around europium(III) (Fig. 11d).
Due to the easy accessibility of water to the three paramagnetic
components per molecule, a relaxivity of up to 31.0 s1 mM1 is
achieved. On the other hand, the exclusion of water from the
first coordination sphere of Eu(III) results in a bright emissive
compound exhibiting a quantum yield up to 10%. Stability
studies revealed relatively high binding constants, paving a way
for further research towards heteropolymetallic f–f assemblies
offering interesting applications in the field of dual imaging.
Table 4 displays a summary of the relaxation rate values and
luminescence quantum yields of the selected complexes.
5 Conclusions and outlook
In the search towards efficient MRI contrast agents, one of the
promising approaches involves the formation of supramole-
cular structures, preferably containing several gadolinium(III)
ions. The slow molecular tumbling time of such higher MW
systems offers the advantage of high proton relaxation rate
values at the magnetic fields of interest, and in addition, the
concentration of several lanthanide ions into a small volume
reinforces this effect. In order to complement the low sensitivity
of MRI, probes suitable for optical imaging with a low detection
limit have been introduced into MRI contrast agents. Dual
imaging contrast agents could provide diagnostic information
at the early stages of the clinical follow up and avoid invasive
procedures. So far, a number of different synthetic procedures
have been reported in order to create bimodal magnetic reso-
nance/optical imaging agents. MRI agents have been coupled to
organic fluorophores or both probes have been incorporated in
lipophilic aggregates or nanosized particles. For these compounds,
broad emission bands and relatively short luminescence life-
times are observed, which makes it difficult to distinguish their
emission from background autofluorescence. The novel trend
involving the combination of multiple lanthanide ions in one
molecule has been a significant breakthrough, since these
compounds offer excellent relaxivity and beneficial lumines-
cence quantum yields with long lifetimes, even under physio-
logical conditions. However, it is important to note that the
limited tissue penetration of visible/near infrared light and
substantial luminescence quenching in an aqueous environ-
ment will restrict in vivo applications of dual agents to imaging
of tissue sections or as markers in surgical operations. Despite
this limitation, molecular imaging plays an essential role in
obtaining more detailed insights into cellular processes and for
discovering diseases in an early stage. Therefore, the search for
optimal imaging probes remains an issue of high priority.
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